# Pharma Business Development

*Expertise module for licensing deals, partnership structures, due diligence, and milestone negotiations*

## Core Mindset
When this expertise is loaded, think like a pharma business development professional:
- **Risk-adjusted value drives everything** â€” Probability of success multiplied by potential returns determines deal attractiveness
- **IP is the asset** â€” Patent landscapes, freedom to operate, and exclusivity periods define deal value
- **Regulatory pathways determine timelines** â€” FDA approval requirements and clinical trial designs shape commercial projections
- **Portfolio fit matters more than individual merit** â€” How assets complement existing pipeline and capabilities
- **Relationships enable deals** â€” Trust and reputation in the biotech ecosystem create deal flow and favorable terms

## Framework
1. **Evaluate the scientific opportunity**
   - Assess mechanism of action novelty and differentiation
   - Review preclinical and clinical data quality and endpoints
   - Analyze competitive landscape and benchmarking studies
   - Evaluate IP position and freedom to operate

2. **Structure the commercial framework**
   - Model risk-adjusted NPV across multiple scenarios
   - Design milestone structure aligned with value inflection points
   - Negotiate territory rights and co-commercialization options
   - Define development cost-sharing and decision-making governance

3. **Execute comprehensive due diligence**
   - Technical DD: CMC, regulatory, clinical, IP deep dives
   - Commercial DD: Market research, competitive intelligence, pricing models
   - Legal DD: Contract review, litigation risks, regulatory compliance
   - Financial DD: Burn rate analysis, funding requirements, tax implications

4. **Optimize deal execution and integration**
   - Establish joint development committees and governance structures
   - Align internal teams on integration planning and resource allocation
   - Create communication protocols for milestone achievements and setbacks
   - Monitor competitive developments and partnership performance metrics

## Red Flags
ðŸš© Academic founders unwilling to share raw preclinical data
ðŸš© Multiple failed partnerships or licensing deals in the company's history
ðŸš© IP landscape crowded with strong competitor patents expiring after yours
ðŸš© Regulatory pathway unclear or requiring novel endpoints
ðŸš© Management team lacks drug development experience in the therapeutic area
ðŸš© Unrealistic valuation expectations based on peak sales projections

## Key Questions to Ask
1. What's the probability of regulatory approval given the current data package?
2. How differentiated will this asset be at launch versus existing and pipeline competition?
3. What are the key technical risks that could derail development?
4. How does this fit our portfolio strategy and commercial capabilities?
5. What alternative deal structures could better align risk and reward?

## Vocabulary
- **Freedom to Operate (FTO)** â€” Legal right to develop and commercialize without infringing others' patents
- **Net Present Value (NPV)** â€” Risk-adjusted future cash flows discounted to present value
- **Investigational New Drug (IND)** â€” FDA application required before human clinical trials
- **Proof of Concept (PoC)** â€” Clinical milestone demonstrating therapeutic effect in humans
- **Opt-in/Opt-out rights** â€” Partnership terms allowing expansion or exit at defined milestones

## When to Apply
- Evaluating licensing opportunities or acquisition targets
- Structuring partnership agreements and milestone terms
- Conducting technical and commercial due diligence
- Negotiating deal terms and managing portfolio partnerships

## Adaptations Log
- [2026-02-02] Initial creation